News

For the nine-month period ended January 31, 2009, the company reported a net loss of $1.02 million, or $0.03 per basic and diluted share, compared to a net

For the year ended December 31, 2008, the company reported a net loss of $14.37 million, or $1.09 per share, an increase of 31%, compared with a net

Under the terms of the three-year, renewable agreement with EKR, ProStrakan will receive undisclosed payments based on the volume of packs of Gelclair that are sold in the

Scientists at Louisiana State University have discovered that bryostatin-1, a potent PKC modulator at nanomolar concentrations, activates protein kinase C-delta (PKC-delta) causing a near complete blockade of leukocyte

As demonstrated in the Athena trial, Multaq is the only anti-arrhythmic drug to have shown in a clinical study a significant reduction in morbidity and mortality in patients

This new solution is based on Sorin’s implanted cardiac rhythm management (CRM) devices’ ability to send data to a non-invasive monitoring system located at the patient’s home and

Under this agreement, Merck Serono, which is the division for prescription pharmaceuticals of the German pharmaceutical and chemical group Merck KGaA, has granted exclusive worldwide rights to Provenance

Mr Surgenor is currently the president, CEO and director of Cyberkinetics Neurotechnology Systems. Prior to becoming president and CEO of Cyberkinetics Neurotechnology Systems, Mr Surgenor was executive vice

The trial, which was a double-blind, placebo-controlled study, was performed at the Rabin Medical Center, Campus Beilinson in Israel. A total of 21 patients were randomized 2:1 to